In-Depth Insights into the Dysautonomia (Autonomic Dysfunction) Market: Growth, Trends, and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the dysautonomia (autonomic dysfunction) market right now?
The market size for dysautonomia, otherwise known as autonomic dysfunction, has witnessed a swift expansion in the previous years. The market that stood at $2.62 billion in 2024 is expected to increase to $2.92 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. The notable growth during the historic period is due to an upsurge in the occurrence of autonomic disorders, a heightened awareness surrounding dysautonomia, increased expenditure on healthcare, extensive research into neurodegenerative diseases, and growing government advocacy for rare diseases.
How fast Is the dysautonomia (autonomic dysfunction) market expected to grow, and what’s its future value?
The market for dysautonomia, also known as autonomic dysfunction, is foreseen to experience swift expansion in the upcoming years. Its value is anticipated to swell to $4.53 billion by 2029, proliferating at a compound annual growth rate (CAGR) of 11.5%. The projected rise over the forecast period can largely be credited to the increasing embrace of personalized medicine, augmentation in clinical trials for innovative treatment methods, surging government support for research on rare ailments, the growth of telemedicine and remote patient monitoring solutions and the enhanced accessibility of orphan drugs. Significant developments expected during the forecast period include the incorporation of artificial intelligence in diagnostic techniques, progress in targeted therapies, utilization of wearable tech for autonomic monitoring, advancements in gene therapies, and innovations in patient-centric treatment modalities.
Get your dysautonomia (autonomic dysfunction) market report here!
What are the leading drivers of growth in the dysautonomia (autonomic dysfunction) market?
The surge in chronic diseases is anticipated to fuel the expansion of the dysautonomia (autonomic dysfunction) market. Chronic disease refers to a health condition that lasts over three months. Factors such as a rising occurrence of multimorbidity, where individuals are diagnosed with many chronic disorders simultaneously, contribute to the rise of chronic diseases. Dysautonomia (autonomic dysfunction) plays a integral part in chronic diseases by interfering with the body’s control of vital functions such as heart rate, blood pressure, and digestion, often making symptoms worse and management more complex. For example, a report by the National Health Service UK in October 2023 showed an increase in Type 1 diabetes prevalence in England from 261,710 cases in 2020-21 to 270,935 cases in 2021-22, a 3.5% year-on-year growth. Thus, the rise in chronic diseases is a driver for the dysautonomia (autonomic dysfunction) market expansion. Growth Of The Market Driven By Increasing Autoimmune And Neurological Disorders
What are the key segments defining the dysautonomia (autonomic dysfunction) market?
The dysautonomia (autonomic dysfunction) market covered in this report is segmented –
1) By Type: Neurogenic Orthostatic Hypotension (NOH), Postural Orthostatic Tachycardia Syndrome (POTS), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Other Types
2) By Tests: Cardiovagal and Vasomotor Function Tests, Thermoregulatory Sweat Test (TST), Sympathetic Skin Response (SSR), Quantitative Sudomotor Axon Reflex Test, Other Tests
3) By Treatment: Physical Therapy, Exercise Therapy, Counseling, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Clinics, Diagnostic Centers, Research Institutes
Subsegments:
1) By Neurogenic Orthostatic Hypotension (NOH): Primary NOH, Secondary NOH (due to Parkinson’s Disease, Diabetes, etc.), Pharmacological Management of NOH, Non-Pharmacological Interventions
2) By Postural Orthostatic Tachycardia Syndrome (POTS): Hyperadrenergic POTS, Hypovolemic POTS, Neuropathic POTS, Autoimmune POTS, Treatment With Beta-Blockers, Fludrocortisone, And Salt Supplements
3) By Multiple System Atrophy (MSA): MSA-P (Parkinsonism), MSA-C (Cerebellar), MSA-A (Autonomic), Disease-Modifying and Symptomatic Treatment
4) By Pure Autonomic Failure (PAF): Idiopathic PAF, Secondary PAF (due to neurodegenerative diseases), Autonomic Supportive Treatments
5) By Other Types: Familial Dysautonomia (FD), Diabetic Autonomic Neuropathy, Horner’s Syndrome, Autoimmune Autonomic Ganglionopathy, Chronic Fatigue Syndrome-related Dysautonomia
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21177&type=smp
Who are the key players steering the development of the dysautonomia (autonomic dysfunction) market?
Major companies operating in the dysautonomia (autonomic dysfunction) market are Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Cadila Healthcare Limited (Zydus Cadila), Lupin Limited, Nemours Children’s Health Delaware, Alnylam Pharmaceuticals Inc., Biohaven Pharmaceuticals Holding Company Ltd., Aurora Health Care Inc., Camber Pharmaceuticals Inc., Theravance Biopharma Inc., Tocris Bioscience, Celltex Therapeutics Corporation, DyAnsys Inc., Axplora Inc., MODAG GmbH, Inhibikase Therapeutics Inc., Mylan Pharmaceuticals Private Limited, Chelsea Therapeutics International Ltd.
What are the key trends shaping the future of the dysautonomia (autonomic dysfunction) market?
Key players in the dysautonomia (autonomic dysfunction) market are striving to progress advancements in gene therapy, such as recombinant adeno-associated virus, in order to boost the conveyance of curative genes to the target cells thereby enhancing treatment results for patients suffering from different types of dysautonomia. Recombinant adeno-associated virus (rAAV) is an altered virus applied in gene therapy for the transfer of genetic material into cells without triggering disease. For instance, in January 2025, US biotech firm, Tikun Therapeutics Inc., secured approval from the Food and Drug Administration (FDA) for the Orphan Drug and Rare Pediatric Disease Designations for rAAV2-U1a-hELP1, a gene therapy aimed at treating optic neuropathy in familial dysautonomia, and BPN-36964, a small molecule splicing modulator directed towards systemic FD treatment. These groundbreaking therapies intend to tackle the root genetic causes of FD, providing prospective long-term benefits beyond symptomatic management.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21177
Which regions are most influential in expanding the dysautonomia (autonomic dysfunction) market?
North America was the largest region in the dysautonomia (autonomic dysfunction) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dysautonomia (autonomic dysfunction) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
IVF Services Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ivf-services-global-market-report
Donor Egg In Vitro Fertilization (IVF) Services Global Market Report 2025
Chronic Cough Global Market Report 2025
https://thebusinessresearchcompany.com/report/chronic-cough-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
